Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,230.12
+0.3%
+21.11
Arrow-Thin-Down
DJI
49,499.27
-0.3%
-152.87
Arrow-Thin-Down
NASDAQ
25,114.44
+0.9%
+222.13
Arrow-Thin-Down
Bitcoin
$80,424.00
+2.9%
+$2,301.67
Arrow-Thin-Down
AAPL
$280.19
+3.3%
+$8.84
Arrow-Thin-Down
AMZN
$268.36
+1.2%
+$3.30
Arrow-Thin-Down
GOOG
$382.96
+0.3%
+$1.02
Arrow-Thin-Down
META
$608.57
-0.5%
-$3.34
Arrow-Thin-Down
MSFT
$414.40
+1.6%
+$6.62
Arrow-Thin-Down
NVDA
$198.61
-0.5%
-$0.96
Arrow-Thin-Down
TSLA
$390.97
+2.4%
+$9.34
Most Active StocksDaily Stock GainersDaily Stock Losers

GlaxoSmithKline to Pay Utah $8.5 Million to Settle Avandia Case

The Utah AG alleged GlaxoSmithKline marketed Avandia nationwide as a "wonder drug" offering a "significant advance" in diabetes treatment, despite evidence it increases the risk of heart attacks for certain users.

By Mark Brooks – Dec 10, 2013 at 2:59PM EST

SALT LAKE CITY (AP) -- Utah will receive $8.5 million from a drugmaker accused of making misleading claims about a new drug for diabetes.

GlaxoSmithKline admitted no wrongdoing in agreeing to settle a lawsuit filed by the Utah Attorney General's Office.

The Utah Attorney General's Office alleged GlaxoSmithKline marketed Avandia nationwide as a "wonder drug" offering a "significant advance" in diabetes treatment, despite evidence it increases the risk of heart attacks for certain users.

Assistant Attorney General Robert Morton represented the state in the negotiations with help from private law firms.

Read Next

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services